These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 24742107)
1. Cyclin E involved in early stage carcinogenesis of esophageal adenocarcinoma by SNP DNA microarray and immunohistochemical studies. Zhou Z; Bandla S; Ye J; Xia Y; Que J; Luketich JD; Pennathur A; Peters JH; Tan D; Godfrey TE BMC Gastroenterol; 2014 Apr; 14():78. PubMed ID: 24742107 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics of high expression of Bmi-1 in esophageal adenocarcinoma and squamous cell carcinoma. Choy B; Bandla S; Xia Y; Tan D; Pennathur A; Luketich JD; Godfrey TE; Peters JH; Sun J; Zhou Z BMC Gastroenterol; 2012 Oct; 12():146. PubMed ID: 23078618 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions. Montgomery E; Mamelak AJ; Gibson M; Maitra A; Sheikh S; Amr SS; Yang S; Brock M; Forastiere A; Zhang S; Murphy KM; Berg KD Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):24-30. PubMed ID: 16540726 [TBL] [Abstract][Full Text] [Related]
4. Vitamin D receptor is highly expressed in precancerous lesions and esophageal adenocarcinoma with significant sex difference. Zhou Z; Xia Y; Bandla S; Zakharov V; Wu S; Peters J; Godfrey TE; Sun J Hum Pathol; 2014 Aug; 45(8):1744-51. PubMed ID: 24951052 [TBL] [Abstract][Full Text] [Related]
6. MCM4 and MCM7, potential novel proliferation markers, significantly correlated with Ki-67, Bmi1, and cyclin E expression in esophageal adenocarcinoma, squamous cell carcinoma, and precancerous lesions. Choy B; LaLonde A; Que J; Wu T; Zhou Z Hum Pathol; 2016 Nov; 57():126-135. PubMed ID: 27476776 [TBL] [Abstract][Full Text] [Related]
7. Anterior gradient 2 profiling in Barrett columnar epithelia and adenocarcinoma. Pizzi M; Fassan M; Realdon S; Balistreri M; Battaglia G; Giacometti C; Zaninotto G; Zagonel V; De Boni M; Rugge M Hum Pathol; 2012 Nov; 43(11):1839-44. PubMed ID: 22521076 [TBL] [Abstract][Full Text] [Related]
8. Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. Fassan M; Pizzi M; Battaglia G; Giacomelli L; Parente P; Bocus P; Ancona E; Rugge M J Clin Pathol; 2010 Aug; 63(8):692-6. PubMed ID: 20702469 [TBL] [Abstract][Full Text] [Related]
9. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus. Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972 [TBL] [Abstract][Full Text] [Related]
10. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma. Bobryshev YV; Lu J; Lord RV J Gastrointest Surg; 2010 Aug; 14(8):1207-13. PubMed ID: 20496011 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949 [TBL] [Abstract][Full Text] [Related]
13. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Hu Y; Bandla S; Godfrey TE; Tan D; Luketich JD; Pennathur A; Qiu X; Hicks DG; Peters JH; Zhou Z Mod Pathol; 2011 Jul; 24(7):899-907. PubMed ID: 21460800 [TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
15. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552 [TBL] [Abstract][Full Text] [Related]
16. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805 [TBL] [Abstract][Full Text] [Related]
17. High-resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma. Sepulveda JL; Komissarova EV; Kongkarnka S; Friedman RA; Davison JM; Levy B; Bryk D; Jobanputra V; Del Portillo A; Falk GW; Sonett JR; Lightdale CJ; Abrams JA; Wang TC; Sepulveda AR Int J Cancer; 2019 Nov; 145(10):2754-2766. PubMed ID: 31001805 [TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854 [TBL] [Abstract][Full Text] [Related]
19. MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Kan T; Meltzer SJ Curr Opin Pharmacol; 2009 Dec; 9(6):727-32. PubMed ID: 19773200 [TBL] [Abstract][Full Text] [Related]
20. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma. Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]